U.S. drugmaker Pfizer suggested it could raise its proposed $106 billion (62.9 billion pounds) offer if AstraZeneca engaged in talks, as its boss was grilled by MPs on his commitment to British research spending and jobs. The New York-based group said it was disappointed by AstraZeneca’s refusal to discuss its proposed merger. Chief Executive Ian Read did not rule out a hostile bid, telling a parliamentary committee he had various \”options\” for his next move.